Crossmark

Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Crossref DOI link: https://doi.org/10.1007/s40257-022-00695-y

Published Online: 2022-06-04

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alavi, Afsaneh https://orcid.org/0000-0003-1171-4917
Raffals, Laura
License Information

Text and Data Mining valid from 2022-06-04

Version of Record valid from 2022-06-04
More Information

Article History

Accepted: 19 April 2021

First Online: 4 June 2022

Declarations

:

: No sources of funding were used to conduct this study or prepare this manuscript.

: Afsaneh Alavi is a consultant for AbbVie, BI, Janssen, InflaRx, Novartis, and UCB and an investigator for BI, Processa. Laura Raffals has no conflicts of interest that are directly relevant to the content of this letter.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below